Partners
Novartis Pharmaceuticals Corporation is the Title and Founding Sponsor of the 2008 U.S. Transplant Games. Through this sponsorship, Novartis continues the long-standing commitment begun by Sandoz with the first Games in 1990 (Sandoz merged with Ciba in December 1996 to form Novartis Pharmaceuticals Corporation). Novartis is focused on enhancing the quality of life for transplant recipients through the development and introduction of novel drugs. As the leader in the field of transplantation, Novartis is also committed to educating the public about the urgent need for organ donation and the life-saving potential of organ transplantation.
Novartis manufactures and markets Neoral® (cyclosporine,USP)MODIFIED Sandimmune® (cyclosporine, USP), Simulect® (basiliximab) and myfortic® (mycophenolic acid). Novartis' contributions to the field of transplantation have had a positive impact on transplant success rates and graft survival and have helped improve the quality of life for transplant recipients.
UPMC is a $7 billion integrated health care enterprise in Pennsylvania and one of the leading academic medical centers in the country. It was one of only 18 hospitals nationwide to earn "honor roll" status in U.S. News & World Report's 2007 "America's Best Hospitals" survey, marking its eighth appearance on that prestigious list. UPMC's transplant programs are the world's largest and busiest; its surgeons perform more types of organ transplants than those at any other institution. On average, UPMC or UPMC-affiliated surgeons perform one transplant every 12 hours. Since 1981, more than 12,000 transplants have been performed, a single-center experience that is unmatched by any other program in the world.
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
Roche continues to expand its commitment to improve the long-term outcomes of transplantation, while enhancing the quality of life for patients. Roche has developed three innovative therapies that improve graft and post-transplant health: Zenapax (daclizumab), used as part of an immunosuppressive regimen to prevent acute rejection of newly transplanted kidneys, CellCept (mycophenolate mofetil), used as part of an immunosuppressive regimen to prevent rejection in kidney, liver and heart transplant patients, and Valcyte (valganciclovir), for the prevention of cytomegalovirus in high-risk kidney, kidney-pancreas and heart transplant patients. Valcyte is not approved for use in liver transplants.
Coca-Cola® Who would have ever thought that what begans as a local soda fountain curiosity on May 8, 1886, would become the world's favorite soft drink? From its simple beginning, Coca-Cola® has grown to be a part of life in cities and towns around the world. It has been over 100 years since Coca-Cola was first served in an Atlanta pharmacy. During this time, the flowing Coca-Cola script has become the best known and most admired trademark in the history of commerce, recognized by nearly all of the world's population.
